益生菌衍生的细胞外囊泡:对于类风湿性关节炎的后生菌的下一个突破
Federica Dell'Atti1,2, Hugo Abreu1,2, Patrizia Malfa3
1Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), Università del Piemonte Orientale, Novara, Italy.
Frontiers in immunology
|August 25, 2025
概括
益生菌衍生的细胞外囊 (EV) 通过调节免疫反应和减少炎症,对类风湿性关节炎 (RA) 具有治疗潜力. 对EV的进一步研究可能会导致RA后生物治疗的突破.
科学领域:
- 免疫学
- 微生物学
- 生物技术
背景情况:
- 风湿性关节炎是一种慢性自身免疫性疾病,涉及全身炎症和关节损伤.
- 肠道和口腔微生物群的失调与RA的发病有关,可能会恶化炎症和免疫失调.
- 益生菌对 RA 是有前途的,但是没有细胞的替代品,如后生菌,包括益生菌衍生的细胞外囊泡 (EV),提供了新的治疗途径.
研究的目的:
- 审查益生菌衍生细胞外囊 (EVs) 对类风湿性关节炎 (RA) 的治疗潜力.
- 检查EV与宿主免疫细胞的相互作用及其随后的免疫调节.
- 讨论使用电动汽车在关节炎治疗和个性化医疗方面的挑战和未来方向.
主要方法:
- 对益生菌衍生的EV,它们的作用机制以及它们在免疫调节中的作用的现有文献进行审查.
- 分析EV与免疫细胞的相互作用,例如促进M2巨分化和抑制促炎细胞因子.
- 探索电气科学和生物技术的进步,以优化电动汽车的生产和应用.
主要成果:
- 益生菌衍生的EV可以调节免疫反应,减少炎症,并恢复肠道屏障的完整性.
- 在抑制促炎细胞因子和促进抗炎M2巨分化方面,EVs具有潜力.
- EVs的治疗效果受其与宿主免疫细胞的相互作用的影响.
结论:
- 益生菌衍生的EV由于其免疫调节性质,代表了对类风湿性关节炎 (RA) 的有前途的后生物疗法.
- 需要解决标准化,管理和临床安全方面的挑战,以获得广泛的临床应用.
- 生物技术和体质科学的进步是释放EVs个性化RA治疗的全部潜力的关键.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
01:36Overview of Exosomes
2.8K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.8K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
01:29Microorganisms in Medicine and Therapeutics
314
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
314
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231